This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182–6 (1971).
Bouck, N., Stellmach, V. & Hsu, S. C. How tumors become angiogenic. Adv Cancer Res 69, 135–74 (1996).
Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–64 (1996).
Polverini, P. J. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 6, 230–47 (1995).
Jimenez, B. & Volpert, O. V. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 78, 663–72 (2001).
Adams, J. C. & Lawler, J. The thrombospondins. Int J Biochem Cell Biol 36, 961–8 (2004).
Tombran-Tink, J. & Barnstable, C. J. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 4, 628–36 (2003).
O'Reilly, M. S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315–28 (1994).
O'Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2, 689–92 (1996).
Sottrup-Jensen, L. Claeys, H. Zajdel, M., Petersen, T.E., Magnusson, S. in Progress in Chemical Fibrinolysis and Thrombolysis (ed. Davidson, J. F., Rowan, RIMI, Samama, M.M., Desnoyers, P.C.) 191–209 (Raven Press, New York, 1978).
Claesson-Welsh, L. et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 95, 5579–83 (1998).
Holmgren, L., O'Reilly, M. S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1, 149–53 (1995).
Wu, Z., O'Reilly, M. S., Folkman, J. & Shing, Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236, 651–4 (1997).
Cao, Y. et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases [published erratum appears in J Clin Invest 1998 Dec 1;102(11):2031]. J Clin Invest 101, 1055–63 (1998).
Gately, S. et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 56, 4887–90 (1996).
Moser, T. L. et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96, 2811–6 (1999).
Wahl, M. L., Owen, C. S. & Grant, D. S. Angiostatin induces intracellular acidosis and anoikis in endothelial cells at a tumor-like low pH. Endothelium 9, 205–16 (2002).
Eriksson, K., Magnusson, P., Dixelius, J., Claesson-Welsh, L. & Cross, M. J. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 536, 19–24 (2003).
Hajitou, A. et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. Faseb J 16, 1802–4 (2002).
Lannutti, B. J., Gately, S. T., Quevedo, M. E., Soff, G. A. & Paller, A. S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57, 5277–80 (1997).
Kirsch, M. et al. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58, 4654–9 (1998).
Tanaka, T., Cao, Y., Folkman, J. & Fine, H. A. Viral vectortargeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 58, 3362–9 (1998).
Ishikawa, H. et al. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 37, 696–704 (2003).
Schmitz, V. et al. Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut 53, 561–7 (2004).
Tao, K. S., Dou, K. F. & Wu, X. A. Expression of angiostatin cDNA in human hepatocellular carcinoma cell line SMMC-7721 and its effect on implanted carcinoma in nude mice. World J Gastroenterol 10, 1421–4 (2004).
Lalani, A. S. et al. Anti-tumor efficacy of human angiostatin using liver-mediated adenoassociated virus gene therapy. Mol Ther 9, 56–66 (2004).
You, W. K. et al. Characterization and biological activities of recombinant human plasminogen kringle 1–3 produced in Escherichia coli. Protein Expr Purif 36, 1–10 (2004).
Yokoyama, Y., Dhanabal, M., Griffloen, A. W., Sukhatme, V. P. & Ramakrishnan, S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60, 2190–6 (2000).
Griscelli, F. et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A 95, 6367–72 (1998).
Chen, Q. R., Kumar, D., Stass, S. A. & Mixson, A. J. Liposomes completed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59, 3308–12 (1999).
Gabison, E. et al. Anti-angiogenic role of angiostatin during corneal wound healing. Exp Eye Res 78, 579–89 (2004).
Kim, J. M. et al. Angiostatin gene transfer as an effective treatment strategy in marine collagen-induced arthritis. Arthritis Rheum 46, 793–801 (2002).
Sumariwalla, P. F., Cao, Y., Wu, H. L., Feldmann, M. & Paleolog, E. M. The angiogenesis inhibitor protease-activated kringles 1–5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 5, R32–9 (2003).
Dabrosin, C., Gyorffy, S., Margetts, P., Ross, C. & Gauldie, J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 161, 909–18 (2002).
Bachman, F. in Hemostasis and Thrombosis. Basic Principles and Clinical Practice (ed. Colman, R. W., Hirsh, J., Marder, V.J., Clowes, A.W., George, J.N.) 275–320 (Lippincott, Williams, and Wilkens, Philadelphia, 2001).
Wojtukiewicz, M. Z., Sierko, E., Klement, P. & Rak, J. The hemostatic system and angiogenesis in malignancy. Neoplasia 3, 371–84 (2001).
Kohli, M., Kaushal, V. & Mehta, P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost 29, 301–8 (2003).
Rijken, D. C. & Collen, D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 256, 7035–41 (1981).
Neuman, T., Stephens, R. W., Salonen, E. M., Timmusk, T. & Vaheri, A. Induction of morphological differentiation of human neuroblastoma cells is accompanied by induction of tissue-type plasminogen activator. J Neurosci Res 23, 274–81 (1989).
Bizik, J., Lizonova, A., Stephens, R. W., Grofova, M. & Vaheri, A. Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion. Cell Regul 1, 895–905 (1990).
Bizik, J., Stephens, R. W., Grofova, M. & Vaheri, A. Binding of tissue-type plasminogen activator to human melanoma cells. J Cell Biochem 51, 326–35 (1993).
McColl, B. K. et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 198, 863–8 (2003).
Stack, M. S., Gately, S., Bafetti, L. M., Enghild, J. J. & Soff, G. A. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 340, 77–84 (1999).
Tarui, T., Majumdar, M., Miles, L. A., Ruf, W. & Takada, Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J Biol Chem 277, 33564–70 (2002).
Muracciole, X. et al. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 52, 592–8 (2002).
Hornm, L. C. et al. Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix. Aust N Z J Obstet Gynaecol 42, 383–6 (2002).
Gately, S. et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A 94, 10868–72 (1997).
Wang, H. et al. Cell surface-dependent generation of angiostatin4.5. Cancer Res 64, 162–8 (2004).
Wang, H., Doll, J.A., Jiang, K., Cundiff, D.L., Soff, G.A. Differential Binding of Plasminogen and Angiostatin4.5 to Cell Surface Beta-Actin: Implications for Cancer-Mediated Angiogenesis. (submitted).
Cao, Y. et al. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells. J Biol Chem 271, 29461–7 (1996).
Cao, Y. et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272, 22924–8 (1997).
O'Reilly, M. S., Wiederschain, D., Stetler-Stevenson, W. G., Folkman, J. & Moses, M. A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274, 29568–71 (1999).
Patterson, B. C. & Sang, Q. A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272, 28823–5 (1997).
Cornelius, L. A. et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161, 6845–52 (1998).
Lijnen, H. R., Ugwu, F., Bini, A. & Collen, D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37, 4699–702 (1998).
Dong, Z., Kumar, R., Yang, X. & Fidler, I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801–10 (1997).
Jurasz, P., Alonso, D., Castro-Blanco, S., Murad, F. & Radomski, M. W. Generation and role of angiostatin in human platelets. Blood 102, 3217–23 (2003).
Falcone, D. J., Khan, K. M., Layne, T. & Fernandes, L. Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen. J Biol Chem 273, 31480–5 (1998).
Heidtmann, H. H. et al. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81, 1269–73 (1999).
Morikawa, W. et al. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 275, 38912–20 (2000).
Li, F. et al. Human glioma cell BT325 expresses a proteinase that converts human plasminogen to kringle 1–5-containing fragments. Biochem Biophys Res Commun 278, 821–5 (2000).
Aggarwal, A., Munoz-Najar, U., Klueh, U., Shih, S. C. & Claffey, K. P. N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am J Pathol 164, 1683–96 (2004).
Soff, G. A. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 19, 97–107 (2000).
Westphal, J. R. et al. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 86, 760–7 (2000).
Soff, G. A. et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96, 2593–600 (1995).
Chen, C., Parangi, S., Tolentino, M. J. & Folkman, J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 55, 4230–3 (1995).
Stathakis, P. et al. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. J Biol Chem 274, 8910–6 (1999).
Stathakis, P., Fitzgerald, M., Matthias, L. J., Chesterman, C. N. & Hogg, P. J. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 272, 20641–5 (1997).
Lay, A. J. et al. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408, 869–73 (2000).
Soff, G. A. et al. Angiostatin4.5: A Naturally occurring human angiogenesis inhibitor. Proc Am Assoc Canc Res 40, #4088 (1999).
O'Mahony, C. A. et al. Angiostatin generation by human pancreatic cancer. J Surg Res 77, 55–8 (1998).
Cao, R. et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 96, 5728–33 (1999).
Scapini, P. et al. Generation of biologically active angiostatin kringle 1–3 by activated human neutrophils. Jlmmunol 168, 5798–804 (2002).
Novokhatny, V. V., Kudinov, S. A. & Privalov, P. L. Domains in human plasminogen. J Mol Biol 179, 215–32 (1984).
Lijnen, H. R., Van Hoef, B., Ugwu, F., Collen, D. & Roelants, I. Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium Sp. Biochemistry 39, 479–88 (2000).
Lerch, P. G., Rickli, E. E., Lergier, W. & Gillessen, D. Localization of individual lysinebinding regions in human plasminogen and investigations on their complex-forming properties. Eur J Biochem 107, 7–13 (1980).
Motta, A., Laursen, R. A., Llinas, M., Tulinsky, A. & Park, C. H. Complete assignment of the aromatic proton magnetic resonance spectrum of the kringle 1 domain from human plasminogen: structure of the ligand-binding site. Biochemistry 26, 3827–36 (1987).
Cao, Y., Cao, R. & Veitonmaki, N. Kringle structures and antiangiogenesis. Curr Med Chem Anti-Canc Agents 2, 667–81 (2002).
Geiger, J. H. & Cnudde, S. E. What the structure of angiostatin may tell us about its mechanism of action. J Thromb Haemost 2, 23–34 (2004).
Ji, W. R. et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. Faseb J 12, 1731–8 (1998).
O'Reilly, M. S. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. Exs 79, 273–94 (1997).
Kim, J. H. et al. The inhibitory effects of recombinant plasminogen kringle 1–3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Exp Mol Med 31, 203–9 (1999).
Cao, Y. Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica 84, 643–50 (1999).
Lee, T. H., Rhim, T. & Kim, S. S. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 273, 28805–12 (1998).
Schulter, V. et al. Impact of apolipoprotein(a) on in vitro angiogenesis. Arterioscler Thromb Vasc Biol 21, 433–8 (2001).
Xin, L., Xu, R., Zhang, Q., Li, T. P. & Gan, R. B. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun 277, 186–90 (2000).
Sheppard, G. S. et al. Lysyl 4-aminobenzoic acid derivatives as potent small molecule mimetics of plasminogen kringle 5. Bioorg Med Chem Lett 14, 965–6 (2004).
Dettin, M. et al. Synthetic peptides derived from the angiostatin K4 domain inhibit endothelial cell migration. Chembiochem 4, 1238–42 (2003).
O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S. & Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285, 1926–8 (1999).
Staton, C. A. et al. Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 103, 601–6 (2004).
Celerier, J., Cruz, A., Lamande, N., Gasc, J. M. & Corvol, P. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 39, 224–8 (2002).
Colorado, P. C. et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60, 2520–6 (2000).
Kamphaus, G. D. et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275, 1209–15 (2000).
O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–85 (1997).
Wen, W., Moses, M. A., Wiederschain, D., Arbiser, J. L. & Folkman, J. The generation of endostatin is mediated by elastase. Cancer Res 59, 6052–6 (1999).
Kim, Y. M. et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60, 5410–3 (2000).
Lee, S. J. et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBSLett 519, 147–52 (2002).
Bootle-Wilbraham, C. A., Tazzyman, S., Marshall, J. M. & Lewis, C. E. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res 60, 4719–24 (2000).
Colman, R. W., Jameson, B. A., Lin, Y., Johnson, D. & Mousa, S. A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95, 543–50 (2000).
Bello, L. et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 61, 8730–6 (2001).
Ferrara, N., Clapp, C. & Weiner, R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129, 896–900 (1991).
Ramchandran, R. et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 255, 735–9 (1999).
Maeshima, Y. et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 276, 15240–8 (2001).
Maeshima, Y. et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295, 140–3 (2002).
Sudhakar, A. et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 100, 4766–71 (2003).
Pike, S. E. et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188, 2349–56 (1998).
Pike, S. E. et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94, 2461–8 (1999).
Walter, J. J. & Sane, D. C. Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration In vitro. Arterioscler Thromb Vase Biol 19, 2041–8 (1999).
Benelli, R. et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. Faseb J 16, 267–9 (2002).
Benelli, R., Morini, M., Brigati, C., Noonan, D. M. & Albini, A. Angiostatin inhibits extracellular HIV-Tat-induced inflammatory angiogenesis. Int J Oncol 22, 87–91 (2003).
Peyruchaud, O., Serre, C. M., NicAmhlaoibh, R., Foumier, P. & Clezardin, P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem 278, 45826–32 (2003).
Wajih, N. & Sane, D. C. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 101, 1857–63 (2003).
Redlitz, A., Daum, G. & Sage, E. H. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vase Res 36, 28–34 (1999).
Gao, G. et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 277, 9492–7 (2002).
Lucas, R. et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92, 4730–41 (1998).
Lu, H. et al. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun 258, 668–73 (1999).
Hanford, H. A. et al. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res 63, 4275–80 (2003).
Das, B., Mondragon, M. O., Sadeghian, M., Hatcher, V. B. & Norin, A. J. A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines. J Exp Med 180, 273–81 (1994).
Veitonmaki, N. et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for kl-5-induced antiangiogenesis. Cancer Res 64, 3679–86 (2004).
Wahl, M. L., Moser, T. L. & Pizzo, S. V. Angiostatin and anti-angiogenic therapy in human disease. Recent Prog Horm Res 59, 73–104 (2004).
Chen, Y. H. et al. Angiostatin antagonizes the action of VEGF-A in human endothelial cells via two distinct pathways. Biochem Biophys Res Commun 310, 804–10 (2003).
Gupta, N. et al. Angiostatin effects on endothelial cells mediated by ceramide and RhoA. EMBO Rep 2, 536–40 (2001).
Sharma, M. R., Tuszynski, G. P. & Sharma, M. C. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem 91, 398–409 (2004).
Tarui, T., Miles, L. A. & Takada, Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 276, 39562–8 (2001).
Troyanovsky, B., Levchenko, T., Mansson, G., Matvijenko, O. & Holmgren, L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152, 1247–54 (2001).
Levchenko, T., Bratt, A., Arbiser, J. L. & Holmgren, L. Angiomotin expression promotes hemangioendothelioma invasion. Oncogene 23, 1469–73 (2004).
Tuszynski, G. P., Sharma, M. R., Rothman, V. L. & Sharma, M. C. Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc Res 64, 448–62 (2002).
Richardson, M. et al. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factorss, which inhibit angiogenesis. Gynecol Oncol 86, 279–87 (2002).
Sten-Linder, M. et al. Angiostatin fragments in urine from patients with malignant disease. Anticancer Res 19, 3409–14 (1999).
Cao, Y. et al. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Int J Mol Med 5, 547–51 (2000).
Sack, R. A., Beaton, A. R. & Sathe, S. Diurnal variations in angiostatin in human tear fluid: a possible role in prevention of corneal neovascularization. Curr Eye Res 18, 186–93 (1999).
Teicher, B. A., Sotomayor, E. A. & Huang, Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52, 6702–4 (1992).
Teicher, B. A., Holden, S. A., Ara, G. & Northey, D. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. Anticancer Res. 13, 2101–6 (1993).
Teicher, B. A. et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57, 920–5 (1994).
Teicher, B. A., Holden, S. A., Ara, G., Korbut, T. & Menon, K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 38, 169–77 (1996).
Wilczynska, U., Kucharska, A., Szary, J. & Szala, S. Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer. Acta Biochim Pol 48, 1077–84 (2001).
Kerbel, R. S. A cancer therapy resistant to resistance. Nature 390, 335–6 (1997).
Boehm, T., Folkman, J., Browder, T. & O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404–7 (1997).
Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27–31 (1995).
Eskens, F. A. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 90, 1–7 (2004).
Mauceri, H. J. et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394, 287–91 (1998).
Gorski, D. H. et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58, 5686–9 (1998).
Mauceri, H. J. et al. Angiostatin potentiates cyclophosphamide treatment of metastatic disease. Cancer Chemother Pharmacol 50, 412–8 (2002).
Galaup, A. et al. Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther 7, 731–40 (2003).
Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105, 1045–7 (2000).
Vacca, A. et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94, 4143–55 (1999).
Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105, R15–24 (2000).
Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60, 1878–86 (2000).
Gately, S. & Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7, 427–36 (2001).
Sim, B. K. et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57, 1329–34 (1997).
MacDonald, N. J., Murad, A. C., Fogler, W. E., Lu, Y. & Sim, B. K. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. Biochem Biophys Res Commun 264, 469–77 (1999).
Meneses, P. I. et al. Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clin Cancer Res 5, 3689–94 (1999).
Beerepoot, L. V. et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res 9, 4025–33 (2003).
Nguyen, J. T., Wu, P., Clouse, M. E., Hlatky, L. & Terwilliger, E. F. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 58, 5673–7 (1998).
Ambs, S., Dennis, S., Fairman, J., Wright, M. & Papkoff, J. Inhibition of tumor growth correlates with the expression level of a human angiostatin transgene in transfected B16F10 melanoma cells. Cancer Res 59, 5773–7 (1999).
Volpert, O. V. et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98, 671–9 (1996).
Vogt, B. & Frey, F. J. Inhibition of angiogenesis in Kaposi's sarcoma by captopril. Lancet 349, 1148 (1997).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Doll, J.A., Soff, G.A. (2005). Angiostatin. In: Platanias, L.C. (eds) Cytokines and Cancer. Cancer Treatment and Research, vol 126. Springer, Boston, MA. https://doi.org/10.1007/0-387-24361-5_8
Download citation
DOI: https://doi.org/10.1007/0-387-24361-5_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24360-3
Online ISBN: 978-0-387-24361-0
eBook Packages: MedicineMedicine (R0)